Brainstorm tapped Minaris to manufacture NurOwn for its upcoming Phase 3b clinical trial testing the treatment for ALS.

Phase 2 data expected in 2H 2026 - - KPL-387 Phase 1 single ascending dose data support profile for monthly dosing - LONDON, ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

Kymera Therapeutics Inc. (NASDAQ:KYMR) announced positive first-in-human results from its Phase 1 healthy volunteer clinical ...

Abstract Title: Rationale and Study Design for a Phase 2/3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to ...

Autonomix Medical receives approval from Republic of Uzbekistan to expand proof-of-concept human clinical study: The Woodlands, Texas Saturday, June 7, 2025, 18:00 Hrs [IST] Auton ...

Estrella Immunopharma Inc. (NASDAQ:ESLA) announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase ...

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

Terence M. Williams, MD, PhD, discussed the phase 1 DINOMITE trial of radiation therapy and papaverine in rectal cancer at ...